• Disease
  • Week
  • Week Patients
  • Jolanta Weglowska

    Prominent publications by Jolanta Weglowska

    KOL Index score: 20967

    BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis.

    METHODS: In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight ≤100 kg and 90 mg for patients >100 kg), or placebo. At week 12, patients receiving brodalumab were ...

    Also Ranks for: Brodalumab Patients |  placebo week |  phase 3 studies |  ustekinumab psoriasis |  monoclonal antibodies


    Jolanta Weglowska: Influence Statistics

    Sample of concepts for which Jolanta Weglowska is among the top experts in the world.
    Concept World rank
    comparing brodalumab #43
    ixekizumab maintenance #44
    amagine2 amagine3 #45
    received ixekizumab #47
    receive brodalumab #51
    amagine3 #53
    210 brodalumab #61
    brodalumab ustekinumab #62
    amagine2 #62
    moderatetosevere psoriasis brodalumab #64
    higher brodalumab #64
    receiving brodalumab #66
    placebo brodalumab #69
    monoclonal humanized candidiasis #70
    brodalumab week #74
    210 140 #75
    brodalumab placebo #89

    Key People For Week Patients

    Top KOLs in the world
    Paul Emery
    rheumatoid arthritis ankylosing spondylitis radiographic progression
    Josef Sebastian Smolen
    rheumatoid arthritis systemic lupus erythematosus radiographic progression
    Désirée M F M van der Heijde
    rheumatoid arthritis ankylosing spondylitis radiographic progression
    Maxime R DOUGADOS
    rheumatoid arthritis ankylosing spondylitis desir cohort
    Arthur F Kavanaugh
    psoriatic arthritis celgene corporation week patients
    Philip J Mease
    psoriatic arthritis eli lilly novartis pfizer

    Jolanta Weglowska:Expert Impact

    Concepts for whichJolanta Weglowskahas direct influence:Week patients,  Brodalumab patients,  Patients brodalumab,  Phase 3 studies,  Placebo week,  Brodalumab placebo,  Plaque psoriasis,  Placebo brodalumab.

    Jolanta Weglowska:KOL impact

    Concepts related to the work of other authors for whichfor which Jolanta Weglowska has influence:Plaque psoriasis,  Psoriatic arthritis,  Monoclonal antibodies,  Brodalumab patients,  Th17 cells,  Biologic agents,  Atopic dermatitis.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    for the IXORA-PEDS Investigators | Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław (J.W.), and Lubelskie Centrum Diagnostyczne, Świdnik (T.B.) — both in Poland